Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.

British journal of clinical pharmacology - 1 Jan 1991

Herchuelz A, Gangji D, Derenne F, Jeanniot J P, Douchamps J

Abstract excerpt

1. Almitrine bismesylate displays wide inter-subject variation in peak plasma concentrations and can induce peripheral polyneuropathy. 2. The phenotyped volunteer panel approach was used to examine whether almitrine oxidation displayed a genetic polymorphism of the debrisoquine/sparteine type. 3. There was no difference between poor and extensive metabolisers of debrisoquine with respect to the pharmacokinetics...

Topics

Adult
Almitrine
Chromatography, High Pressure Liquid
Debrisoquin
Female
Humans
Male
Oxidation-Reduction
Phenotype
Polymorphism, Genetic
Sparteine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 2015173
DOI: 10.1111/j.1365-2125.1991.tb03859.x
PMCID: PMC1368414

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-2015173-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.PMID 2015173Read ↗

Determination of debrisoquine oxidation phenotype in healthy volunteers during phase I trials.Semantic proximity Read ↗

Genetically determined adverse drug reactions involving metabolism.Semantic proximity Read ↗

Polymorphic debrisoquin metabolism in a Turkish population.Semantic proximity Read ↗

Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes.Semantic proximity Read ↗

Effect of diurnal variation on debrisoquine metabolic phenotyping.Semantic proximity Read ↗

Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population.Semantic proximity Read ↗

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation CapacitySemantic proximity Read ↗

Evidence for the polymorphic oxidation of debrisoquine in the Thai population.Semantic proximity Read ↗

Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers.Semantic proximity Read ↗

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.Semantic proximity Read ↗

Debrisoquine oxidation in an Italian population: a study in healthy subjects and in schizophrenic patients.Semantic proximity Read ↗

Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.